Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
Harvard University · Beth Israel Deaconess Medical Center · +7 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
135
total citations
- FWCI
- 47.91
- Percentile
- 100%
- References
- 71
Citations per year
Authors
7- MKMichail Kokkorakis
Harvard University, Beth Israel Deaconess Medical Center, University of Groningen, University Medical Center Groningen
- CBChrysoula Boutari
Harvard University, Beth Israel Deaconess Medical Center
- MAMichael A. Hill
University of Missouri
- VKVasilios Kotsis
Papageorgiou General Hospital
- RLRohit Loomba
University of California, San Diego
Topics & keywords
Topics
Keywords
- Steatohepatitis
- Medicine
- Drug
- Intensive care medicine
- Internal medicine
- Pharmacology
- Fatty liver
- Disease
No related works found for this paper.
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GSGilead Sciences
- APAlnylam Pharmaceuticals
- RPRegeneron Pharmaceuticals
- MLMassachusetts Life Sciences Center
- APArrowhead Pharmaceuticals
- BPBoston Pharmaceuticals
- CBCoherus Biosciences
- NNNovo Nordisk
- UMUniversitair Medisch Centrum Groningen
- LCLG Chem
- ETEsperion Therapeutics
- GGenentech
- NINational Institute on Alcohol Abuse and AlcoholismAward: U01AA029019
- NHNational Heart, Lung, and Blood InstituteAwards: P30DK120515, U01AA029019, P01HL147835
- NINational Institute of Diabetes and Digestive and Kidney DiseasesAwards: R01DK121378, P30DK120515, U01DK061734, U01DK130190, R01DK106419, R01DK124318
- NCNational Center for Advancing Translational SciencesAwards: U01DK061734, U01DK130190, P30DK120515, R01DK121378, 5UL1TR001442, R01DK124318, R01DK106419